Testosterone Therapy for Women: A Complete Guide to Benefits, Risks, Dosing, and Monitoring

For many women, a change in sexual desire can be one of the more confusing parts of midlife.

A woman may still love her partner. She may still enjoy intimacy once it begins. Yet the spontaneous desire she once experienced may be noticeably quieter. Sex may rarely cross her mind. Initiating intimacy may feel less natural, and the change may be significant enough that she misses an important part of herself.

Sometimes this happens during perimenopause or after menopause. Sometimes it follows removal of the ovaries. And sometimes it occurs without an obvious hormonal turning point.

When women begin looking for answers, the conversation usually centers on estrogen and progesterone. Testosterone is often overlooked.

Yet testosterone is also a normal female hormone.

Women produce testosterone throughout life, and androgen receptors are present in tissues throughout the body. Testosterone participates in sexual physiology and interacts with the brain, reproductive tissues, muscle, bone, and other systems. Its role in women’s health is real, but that does not mean every symptom associated with aging or menopause can be treated by giving more testosterone.

That distinction is essential.

The strongest clinical evidence for testosterone therapy in women is much narrower than many online claims suggest. Current international guidance supports appropriately dosed testosterone primarily for postmenopausal women with hypoactive sexual desire disorder (HSDD) after other contributors to low sexual desire have been evaluated.

For the right patient, treatment can be meaningful. For the wrong problem, however, testosterone may provide little benefit while exposing the patient to unnecessary androgen effects.

Understanding where testosterone fits begins with understanding what testosterone actually does in the female body.

Women Naturally Produce Testosterone

Testosterone is frequently described as a “male hormone,” but that description is biologically incomplete.

Men generally have much higher circulating testosterone concentrations, but women also produce testosterone and other androgens. During the reproductive years, androgen production involves both the ovaries and adrenal glands, along with conversion of androgen precursors in peripheral tissues.

Testosterone can act directly through androgen receptors. It can also be converted into other biologically active hormones within tissues. Through the enzyme 5-alpha-reductase, testosterone can be converted to dihydrotestosterone (DHT), a more potent androgen. Through aromatase, testosterone can be converted to estradiol.

This means testosterone participates in a much larger hormonal network rather than functioning in isolation.

That network also helps explain why a blood testosterone result does not tell the entire story.

Total Testosterone Is Not the Same as Biologically Available Testosterone

Most testosterone circulating in the bloodstream is attached to proteins.

One of the most important is sex hormone-binding globulin (SHBG). Testosterone that is tightly bound to SHBG is much less readily available to tissues. Another portion is more loosely bound to albumin, while only a small fraction circulates unbound.

As a result, two women can have similar total testosterone measurements but different hormonal environments because their SHBG concentrations differ.

SHBG itself can be influenced by several factors, including oral estrogen therapy, estrogen-containing contraceptives, thyroid status and thyroid hormone therapy, liver function, metabolic factors, and other medications or medical conditions.

This is one reason testosterone therapy should not be reduced to simply “raising a number.”

The clinical question is not:

Is this woman’s testosterone below an arbitrary target?

The better question is:

Does she have a clinical problem for which testosterone has evidence of benefit, and can treatment be used safely while keeping exposure within the normal physiologic female range?

Those are very different approaches.

What Happens to Testosterone as Women Age?

One of the most common misconceptions is that testosterone suddenly collapses at menopause in the same way ovarian estrogen production changes.

The physiology is more complicated.

Research examining androgen concentrations across adulthood has found that testosterone and several other androgens tend to decline substantially with age, particularly beginning earlier in adult life. Natural menopause itself does not necessarily produce an abrupt testosterone “deficiency” at the final menstrual period.

The ovaries can continue contributing to androgen production after menopause.

The situation is different after bilateral oophorectomy, meaning surgical removal of both ovaries. Women who have undergone this procedure can experience a more substantial reduction in circulating testosterone because an important source of androgen production has been removed.

These distinctions matter clinically because they challenge a popular but oversimplified idea:

Menopause does not automatically mean testosterone deficiency.

In fact, major endocrine organizations have advised against diagnosing a generalized “androgen deficiency syndrome” in otherwise healthy women because there is no well-established testosterone concentration below which a predictable group of symptoms reliably develops.

A laboratory result alone therefore cannot diagnose the condition for which testosterone therapy is best supported.

So Why Can Testosterone Therapy Help Some Women?

The best-established therapeutic effect involves the brain and sexual response.

Sexual desire is not controlled by a single hormone. It emerges from interactions among the brain, sex hormones, physical comfort, emotional health, medications, relationships, sleep, stress, previous experiences, and many other influences.

Testosterone is one part of this system.

Clinical trials in postmenopausal women have found that physiologic testosterone therapy can improve several dimensions of sexual function, including sexual desire, arousal, pleasure, orgasmic function, responsiveness, and sexual satisfaction, while reducing sexual distress.

A large systematic review and meta-analysis evaluated 36 randomized controlled trials involving 8,480 women. Compared with placebo or comparator treatment, testosterone produced statistically significant improvements across several measures of sexual function in postmenopausal women.

But this finding needs to be interpreted correctly.

It does not mean testosterone should be prescribed to every woman who reports low libido.

The women most likely to fit the evidence-based indication are those with a condition known as hypoactive sexual desire disorder.

Understanding Hypoactive Sexual Desire Disorder

Sexual desire naturally varies enormously among women.

It can change with age, relationships, parenting, work demands, illness, sleep, medications, menopause, and countless other circumstances. A lower level of desire is not automatically a medical disorder.

This distinction is important because medicine should not turn normal variation in sexuality into disease.

HSDD involves more than simply wanting sex less frequently than someone else.

In practical terms, it involves a persistent or recurrent reduction or absence of sexual desire that causes meaningful personal distress and cannot be better explained by another primary cause.

The distress component matters.

If a woman has relatively little interest in sex but is comfortable with that and does not experience distress because of it, testosterone treatment should not automatically be assumed to be necessary.

If, on the other hand, a woman says:

“This is different from who I used to be. I miss wanting intimacy, and the change bothers me,”

that deserves thoughtful evaluation.

The next question is why the change occurred.

Low Libido Is Not Always a Testosterone Problem

One of the most important parts of evaluating low sexual desire is looking beyond testosterone.

Sexual function is biopsychosocial. Biology matters, but so do psychological, interpersonal, medication-related, and physical factors.

A thoughtful evaluation may consider:

• Menopause and other hormonal changes
• Vaginal dryness or painful intercourse
• Genitourinary syndrome of menopause
• Depression or anxiety
• Chronic stress
• Sleep problems
• Fatigue
• Relationship concerns
• Body-image concerns
• Previous sexual trauma
• Chronic medical conditions
• Medication adverse effects
• Alcohol or substance use
• Partner sexual difficulties
• Thyroid disorders or other endocrine conditions when clinically suspected

Certain medications can also affect sexual desire. Antidepressants, particularly some serotonergic antidepressants, are a familiar example, although medications should never be stopped or changed without discussing the risks and alternatives with the prescribing clinician.

Pain deserves particular attention.

A woman who develops vaginal dryness and pain with intercourse after menopause may understandably begin avoiding sexual activity. Over time, anticipation of discomfort can suppress desire.

In that situation, addressing genitourinary syndrome of menopause, vaginal dryness, or another source of pain may be more important than adding testosterone.

This illustrates a central principle of women’s sexual medicine:

Treat the reason for the symptom, not simply the symptom itself.

Can a Testosterone Blood Test Diagnose Low Testosterone in Women?

Not in the way many people expect.

There is currently no validated testosterone cutoff that diagnoses HSDD.

A woman can have a testosterone concentration in the lower portion of a laboratory reference interval without having sexual symptoms. Another woman may have distressing low desire despite a testosterone result that does not appear unusually low.

For this reason, major consensus recommendations specifically caution against using total testosterone concentration to diagnose HSDD.

That does not mean laboratory testing has no value.

It means the test has a different purpose.

Before treatment, testosterone testing can help establish a baseline and identify women whose concentrations are already relatively high. During treatment, measurements can help clinicians avoid excessive exposure and keep concentrations from rising above the physiologic female range.

In other words:

The laboratory test is primarily a safety and monitoring tool, not a libido score.

That is an important distinction for patients to understand.

Who May Be a Candidate for Testosterone Therapy?

The strongest evidence supports testosterone therapy for appropriately evaluated postmenopausal women with HSDD.

This can include women who went through natural menopause as well as women who became menopausal after surgical removal of the ovaries.

Treatment should generally follow a comprehensive assessment rather than being prescribed simply because a laboratory value appears low.

The Global Consensus Position Statement on testosterone therapy for women concluded that HSDD in postmenopausal women is the only indication supported by sufficient evidence.

The International Society for the Study of Women’s Sexual Health (ISSWSH) subsequently developed more detailed clinical guidance for using systemic testosterone in this setting.

There is considerably less evidence for testosterone treatment in premenopausal women. Some expert guidance discusses limited circumstances in later reproductive life, but the evidence is not nearly as robust as it is for postmenopausal HSDD.

This is one of several areas in which individualized clinical judgment and careful counseling are important.

What Testosterone Therapy Can Realistically Accomplish

Patients deserve realistic expectations.

Testosterone is not an instant switch for libido.

Across clinical trials, appropriately selected postmenopausal women experienced improvements in several aspects of sexual function. In the Global Consensus analysis, physiologic testosterone therapy produced an average increase of approximately one additional satisfying sexual event per month above placebo or comparator therapy, along with improvements in desire, arousal, orgasm, pleasure, responsiveness, and sexual distress.

For some women, the improvement may feel more meaningful than that average suggests. Others experience little or no benefit.

This is why testosterone therapy is best viewed as a therapeutic trial with defined goals, not a hormone that must be continued indefinitely simply because treatment was started.

Before beginning therapy, it can be helpful for the patient and clinician to identify what improvement would actually look like.

For example:

• Thinking about sex more often
• Feeling more receptive to intimacy
• Experiencing spontaneous desire again
• Initiating intimacy more frequently
• Experiencing greater arousal or pleasure
• Feeling less distress about loss of sexual interest

Those outcomes are often more meaningful than chasing a particular testosterone number.

What Testosterone Has Not Been Proven to Treat

This is one of the most important sections of any balanced discussion of testosterone therapy for women.

Testosterone is increasingly promoted for a broad collection of symptoms, including:

• Fatigue
• Brain fog
• Weight gain
• Depression
• Low motivation
• Loss of muscle
• Poor sleep
• Bone loss
• General aging
• “Hormone optimization”
• Overall well-being

Some women using testosterone may report improvement in one or more of these areas.

Patient experience should not be dismissed.

However, an individual experience and an established medical indication are not the same thing.

Current consensus evidence does not establish systemic testosterone as a treatment for cognitive function, general well-being, prevention of cardiovascular disease, metabolic health, bone health, or disease prevention in otherwise healthy women.

Studies have also not established testosterone as a general anti-aging treatment.

This distinction protects patients from a common problem in hormone medicine: assuming that because a hormone participates in a biological process, increasing that hormone must improve the process.

Human physiology rarely works that simply.

Testosterone Is Not a Weight-Loss Medication

Another increasingly common claim is that testosterone can help women lose weight or dramatically change body composition.

At physiologic doses studied in women, evidence has not established testosterone therapy as an effective weight-loss treatment.

Muscle tissue contains androgen receptors, and testosterone clearly influences muscle physiology. But translating that biology into a recommendation to prescribe testosterone for weight loss or routine muscle building in women is not supported by current evidence.

Women experiencing midlife changes in body composition should instead be evaluated in the broader context of physical activity, resistance training, nutrition, sleep, menopausal changes, insulin resistance, medications, thyroid disease when appropriate, and other metabolic factors.

Testosterone should not substitute for that evaluation.

Testosterone Therapy Is Different From Menopausal Estrogen Therapy

Women sometimes hear the phrase “hormone therapy” and understandably assume estrogen, progesterone, and testosterone are interchangeable components of one treatment strategy.

They are not.

Estrogen has well-established indications in menopause medicine, including treatment of bothersome vasomotor symptoms such as hot flashes and night sweats. Estrogen therapy also plays an important role in genitourinary syndrome of menopause and prevention of bone loss in appropriately selected women.

Progesterone or another progestogen may be necessary to protect the endometrium when systemic estrogen is prescribed to a woman with a uterus, depending on the treatment regimen.

Testosterone serves a different purpose.

Current evidence does not support simply adding testosterone to every menopausal hormone regimen.

Hormone therapy should be built around the patient’s actual symptoms, medical history, treatment goals, and risk profile rather than around the idea that every hormone that declines with age needs to be “replaced.”

Testosterone Therapy for Women in the United States Is Usually Off-Label

This is an important practical issue.

At present, the United States does not have an FDA-approved testosterone product specifically indicated for women with HSDD.

FDA-approved testosterone products in the United States are designed and labeled for certain indications in men.

Consequently, when clinicians prescribe testosterone to women, treatment generally involves off-label prescribing or, in selected circumstances, a compounded preparation.

Off-label prescribing is common throughout medicine and does not inherently mean a treatment is inappropriate. It means the FDA-approved labeling for that particular commercial product does not include the specific use being prescribed.

The challenge with testosterone is dosing.

A typical male testosterone product delivers substantially more testosterone than is needed to achieve physiologic concentrations in women. When a male formulation is used off-label, only a fraction of the male dose may be appropriate.

That makes careful prescribing, patient education, and follow-up particularly important.

How Testosterone Is Usually Given to Women

For HSDD, the strongest evidence and major clinical guidelines favor transdermal testosterone, meaning testosterone delivered through the skin.

Transdermal delivery may involve a gel or cream.

The objective is not to produce male testosterone concentrations.

The objective is to provide a small amount of testosterone that maintains exposure within the physiologic range expected in premenopausal women.

That principle is fundamental:

Female testosterone therapy should use female physiologic exposure.

More is not better.

Increasing testosterone above the normal female range in an attempt to obtain faster or stronger results increases the risk of androgenic adverse effects without establishing greater therapeutic benefit.

Why Dose Precision Matters So Much

Testosterone is potent.

The quantities used for women can be much smaller than those found in commercial products designed for men.

That creates practical challenges.

If a product is too concentrated for the measuring system being used, small variations in the amount applied may translate into meaningful differences in dose. Conversely, an appropriately designed formulation and dispensing system can make small doses easier to administer consistently.

This is one area in which pharmacists can be particularly helpful.

Patients should understand:

• How much medication to apply
• How the prescribed quantity corresponds to the intended dose
• Where it should be applied
• How frequently it should be used
• What to do after application
• How to minimize transfer to another person
• What adverse effects should be reported

Consistency matters more than trying to make tiny day-to-day adjustments based on symptoms.

Hormones should not be self-titrated without guidance from the prescribing clinician.

Where Is Topical Testosterone Applied?

Application instructions depend on the specific formulation and prescriber’s directions.

Transdermal testosterone is generally applied to clean, dry skin in an area recommended for that particular product. Patients should follow the pharmacy label and counseling instructions rather than assuming all testosterone creams or gels are interchangeable.

After application, the medication should generally be allowed to dry or absorb as directed.

Patients should wash their hands thoroughly after handling topical testosterone.

They should also be aware of secondary transfer.

Testosterone remaining on the skin can potentially transfer to another person through direct skin contact. This is particularly important around children, partners, and pregnant individuals.

Depending on the formulation, patients may be advised to allow the site to dry, cover the application area with clothing, and avoid direct skin-to-skin contact with the treated area for an appropriate period.

If another person accidentally contacts an application site, washing the exposed skin with soap and water is generally prudent.

The exact precautions should follow the dispensed product’s instructions.

When Should Improvement Occur?

Hormone therapy should not be judged after only a few applications.

Clinical guidance suggests that improvement in sexual desire may begin after several weeks, with effects developing over the following months.

Some women notice meaningful changes within approximately 4 to 8 weeks. Maximum benefit may take longer.

If there has been no meaningful improvement after an adequate therapeutic trial, often by about six months, continuing testosterone indefinitely usually makes little sense.

At that point, the clinician should reconsider the diagnosis, treatment adherence, dose, formulation, SHBG and testosterone concentrations where appropriate, medications, pain, relationship factors, psychological contributors, and other potential causes of low desire.

Treatment failure can itself provide useful clinical information.

Monitoring Testosterone Therapy

Good testosterone therapy is not simply a prescription followed by “see you next year.”

Monitoring helps answer two different questions:

1. Is the patient benefiting?
2. Is testosterone exposure remaining within a safe physiologic range?

Before treatment, clinicians commonly obtain a baseline total testosterone concentration. ISSWSH guidance also recommends measuring SHBG because an elevated SHBG concentration may influence testosterone availability and treatment response.

Depending on the patient’s medical history and clinician’s approach, additional baseline evaluation may be appropriate.

After treatment begins, testosterone is generally rechecked within several weeks. ISSWSH guidance recommends reassessment of total testosterone approximately 3 to 6 weeks after initiation, with repeat testing after dose changes.

Once treatment and concentrations are stable, periodic monitoring can continue, commonly every several months.

The purpose is not to push the testosterone level toward the top of the range.

It is to ensure the patient is not receiving excessive testosterone.

The clinical response matters at least as much as the laboratory value.

Why “Optimal Testosterone Levels” Can Be Misleading

Patients sometimes encounter clinics or online sources that promote a specific “optimal” testosterone concentration for every woman.

That concept should be approached cautiously.

There is no universally established testosterone concentration at which women reliably experience optimal sexual function, energy, mood, or well-being.

Laboratory methods also differ, and testosterone is more difficult to measure accurately at the relatively low concentrations normally present in women.

The appropriate reference range should therefore be interpreted in the context of the laboratory method, patient age, clinical situation, and treatment.

Guidelines emphasize preventing supraphysiologic exposure, rather than escalating treatment until a predetermined “optimal” number is reached.

A woman who feels well does not need an artificially elevated testosterone concentration simply because a higher number has been marketed as ideal.

Potential Side Effects of Testosterone Therapy

When testosterone is maintained within physiologic female concentrations, clinical trials suggest that treatment is generally well tolerated in appropriately selected women over the durations studied.

The most familiar adverse effects are androgenic.

These can include:

• Acne
• Increased facial or body hair
• Oily skin
• Scalp hair thinning in susceptible individuals

These effects are often dose related.

Higher, supraphysiologic testosterone exposure creates greater concern for signs of virilization, including:

• Voice deepening
• Clitoral enlargement
• More pronounced facial or body hair growth
• Androgenic hair loss

Some virilizing changes may not be fully reversible.

For that reason, symptoms of androgen excess should never simply be accepted as proof that testosterone is “working.”

They may be evidence that exposure is too high.

Patients experiencing new or progressive androgenic symptoms should contact their prescriber.

What About Cholesterol and Cardiovascular Risk?

Route of administration matters.

Oral testosterone preparations can adversely affect lipid profiles and are generally not recommended for this indication.

Nonoral testosterone used in physiologic female doses has not demonstrated the same adverse short-term lipid effects in available randomized trials.

However, there is an important limitation.

Many testosterone trials excluded women at higher cardiometabolic risk, and long-term cardiovascular safety data in women remain incomplete.

Therefore, absence of a demonstrated short-term cardiovascular signal should not be translated into a claim that testosterone prevents cardiovascular disease or has been proven safe for every woman indefinitely.

Medical history still matters.

What Do We Know About Breast Cancer Risk?

Available randomized trial data have not established an increase in breast cancer risk from short-term physiologic transdermal testosterone therapy.

But long-term data are insufficient to make strong conclusions about breast cancer risk over many years of treatment.

That uncertainty should be discussed openly rather than minimized.

Women with a personal history of hormone-sensitive breast cancer or other complex hormone-dependent conditions require individualized evaluation with the clinicians managing their cancer and women’s health care.

Testosterone should not be assumed to be hormonally irrelevant to breast tissue simply because it is an androgen.

Some testosterone can be converted to estradiol through aromatase, and sex-steroid biology is interconnected.

Testosterone and Pregnancy

Testosterone therapy is not appropriate during pregnancy.

Women who still have pregnancy potential should discuss contraception and reproductive plans with their healthcare provider before treatment.

Menopause status should also not be assumed solely from symptoms, particularly during perimenopause when ovulation can be irregular but still occur.

A patient who becomes pregnant or believes she may be pregnant while using testosterone should promptly contact her healthcare provider.

Why Oral Testosterone Is Generally Avoided

Testosterone can be administered through several routes, but they are not clinically equivalent.

Oral testosterone has been associated with unfavorable lipid effects and is not recommended by major consensus guidance for treatment of HSDD in women.

Transdermal therapy has therefore become the preferred evidence-based systemic route when testosterone is prescribed.

The route matters because a hormone’s effects are determined not only by the molecule itself but also by how it enters the body, how quickly concentrations rise and fall, how the liver processes it, and how consistently exposure can be controlled.

This principle applies throughout hormone therapy.

What About Testosterone Injections?

Injectable testosterone products can produce substantial peaks in testosterone concentration depending on the formulation and dose.

Because female physiologic doses are small, avoiding excessive exposure can be more difficult with preparations designed to deliver much larger amounts of testosterone.

For HSDD in women, consensus recommendations favor formulations that maintain physiologic female concentrations and caution against approaches that create supraphysiologic levels.

This is one reason transdermal therapy is generally preferred.

What About Testosterone Pellets?

Pellet therapy has become highly visible in some hormone clinics.

A testosterone pellet is implanted beneath the skin and gradually releases testosterone over an extended period.

The convenience may sound appealing because daily application is unnecessary.

However, there is an important clinical disadvantage:

Once a pellet has been inserted, the dose cannot easily be adjusted or withdrawn.

If testosterone exposure becomes excessive or adverse effects occur, clinicians cannot simply reduce tomorrow’s application in the way they can with a topical product.

Major consensus guidance does not recommend testosterone preparations that result in supraphysiologic concentrations, including pellets in that context. ACOG specifically recommends considering testosterone delivery methods other than pellets because of limited safety data and the inability to remove the medication easily after implantation.

This does not mean every woman who has ever received a pellet will experience harm.

It means the pharmacologic limitations of pellets deserve to be part of informed consent.

Compounded Testosterone Therapy

Compounding has a legitimate role in patient care when an appropriate commercially available product does not meet a patient’s clinical needs.

Testosterone therapy for women presents a unique situation in the United States because there is currently no FDA-approved testosterone formulation specifically designed and approved for female HSDD.

A prescriber may therefore consider an off-label fraction of an FDA-approved male transdermal product or, in selected circumstances, a compounded testosterone formulation.

Compounding can allow a medication to be prepared in a concentration, dosage form, base, or dispensing system specifically prescribed for an individual patient.

For testosterone, this may be useful when the very small doses required for women are difficult to administer consistently using commercially available male products.

However, compounded medications are not FDA-approved products. They do not undergo the same FDA premarket review for safety, efficacy, pharmacokinetics, and manufacturing consistency as an approved drug.

Professional organizations therefore generally recommend FDA-approved products when a suitable approved formulation exists.

Because there is no FDA-approved female testosterone formulation in the United States, treatment decisions require a more nuanced discussion among the patient, prescriber, and pharmacist.

If compounded testosterone is selected, the goal should remain the same:

Use the lowest appropriate dose that provides clinical benefit while avoiding supraphysiologic testosterone exposure.

Compounding should facilitate individualized dosing. It should not be used as justification for pushing hormone concentrations beyond normal female physiology.

“Bioidentical” Does Not Automatically Mean Safer

The word bioidentical is frequently used in hormone therapy marketing.

Chemically, the term generally refers to a hormone that is structurally identical to the hormone produced by the human body.

But “bioidentical” does not tell you whether a medication is FDA approved, compounded, safe for a particular patient, appropriately dosed, or supported by evidence for a particular indication.

FDA-approved estradiol and micronized progesterone products, for example, can also contain hormones structurally identical to endogenous human hormones.

Likewise, a compounded hormone can be bioidentical but still require the same careful prescribing, monitoring, and risk assessment as any other medication.

The more useful questions are:

• What hormone is being prescribed?
• Why is it being prescribed?
• What evidence supports that use?
• What dose is being used?
• What route is being used?
• How will treatment be monitored?
• What are the potential risks and alternatives?

Those questions tell patients far more than the word “bioidentical.”

Testosterone Should Not Be Dosed From Saliva Testing

Another practice patients may encounter is hormone dosing based on salivary hormone measurements.

Major professional guidance does not support routine salivary hormone testing to determine menopausal hormone doses.

Hormone concentrations fluctuate, assay limitations exist, and tissue exposure cannot be reliably inferred from a single salivary measurement.

For testosterone therapy, clinical assessment combined with appropriately performed serum testing is more useful.

Even serum testosterone, however, should not be used to “treat to a number.”

Its most important role during therapy is helping clinicians avoid excessive exposure.

What If Testosterone Is Low but Libido Is Normal?

Usually, a laboratory number by itself is not a reason to prescribe testosterone.

This is one of the clearest examples of why treating patients rather than laboratory values matters.

Current guidelines do not recognize a generalized testosterone-deficiency syndrome in healthy women based solely on a low blood concentration.

If a woman feels well, has no distressing sexual symptoms, and has an unexpectedly low testosterone result, the appropriate response is not automatically to prescribe testosterone.

The clinician should first consider why the test was ordered, the assay used, medications, SHBG, medical history, and whether the result has any clinical significance.

Hormones are not nutritional vitamins that must simply be replenished whenever a laboratory value appears toward the lower end of a range.

What If Testosterone Is Normal but Libido Is Low?

A normal testosterone level does not rule out HSDD.

This can initially seem contradictory.

If testosterone therapy can help HSDD, why wouldn’t low testosterone be required?

Because sexual desire is not determined by serum testosterone concentration alone.

Clinical trials have not identified a testosterone cutoff that reliably separates women with HSDD from women without it, nor does baseline endogenous testosterone reliably predict who will respond.

That is why HSDD is fundamentally a clinical diagnosis.

Testosterone measurement helps clinicians prescribe safely. It does not determine whether a woman is allowed to experience a sexual symptom.

Should Testosterone Be Combined With Estrogen?

Not necessarily.

Clinical trials have demonstrated testosterone benefits in postmenopausal women both with and without concurrent estrogen therapy.

Whether a woman should also use estrogen depends on her own menopausal symptoms, medical history, risk factors, uterine status, age, time since menopause, and treatment goals.

For example, a woman with bothersome hot flashes and vaginal symptoms may have reasons to consider menopausal estrogen therapy independently of her sexual desire.

Another woman may have HSDD without needing systemic estrogen.

Hormones should not automatically be bundled together.

Each should have a reason for being prescribed.

What About Vaginal Dryness and Painful Sex?

Low sexual desire and painful intercourse frequently overlap, but they should not be assumed to be the same condition.

After menopause, declining estrogen can cause changes in the vulva, vagina, bladder, and urethra collectively known as genitourinary syndrome of menopause (GSM).

Symptoms may include:

• Vaginal dryness
• Burning or irritation
• Pain with penetration
• Reduced lubrication
• Urinary discomfort
• Recurrent urinary symptoms

If intercourse becomes painful, desire may understandably fall.

For GSM, evidence-based treatments may include vaginal moisturizers and lubricants, local vaginal estrogen, vaginal DHEA, and other therapies depending on the patient’s situation.

Treating pain can sometimes improve sexual interest without requiring systemic testosterone.

This is why a careful sexual-health evaluation should separate desire, arousal, orgasm, and pain rather than treating all sexual concerns as “low libido.”

A Practical Example

Consider two women who both say, “My libido disappeared after menopause.”

The first also reports severe vaginal dryness and burning. Intercourse has become painful, and she has gradually stopped wanting sex because she anticipates discomfort.

The second has no pain and still enjoys intimacy when it occurs, but rarely experiences desire or sexual thoughts anymore. She finds the change distressing and misses the sexual part of her life.

Their opening complaint sounds identical.

Their treatment plans may be completely different.

The first woman’s care may focus primarily on treating GSM and restoring comfortable sexual activity.

The second may warrant evaluation for HSDD and, if other contributors have been addressed, could potentially be a candidate for testosterone therapy.

That is personalized medicine in its most useful form: not making every treatment unique simply for the sake of customization, but identifying which problem actually needs to be solved.

What a Good Testosterone Consultation Should Include

A thoughtful consultation should go beyond ordering a hormone panel.

The clinician should understand what changed, when it changed, how distressing it is, and what else was happening at the time.

Useful questions include:

What does “low libido” mean to you?

Some women mean they never spontaneously think about sex. Others mean they cannot become aroused. Others experience pain. Others can become aroused but cannot reach orgasm.

Those are not necessarily the same problem.

Did the change happen suddenly or gradually?

A sudden change may prompt consideration of a new medication, illness, surgery, relationship event, or other trigger.

Is sex physically comfortable?

Pain changes desire.

Did symptoms begin after starting a medication?

Medication review can be extremely important.

Is the loss of desire personally distressing?

This helps distinguish HSDD from a level of desire that is simply lower than in the past but not problematic to the patient.

What would successful treatment look like?

This establishes a meaningful therapeutic endpoint.

Good hormone therapy begins with good questions.

Integrative Perspective

Testosterone can be part of sexual-health treatment, but sexual desire does not exist separately from the rest of a woman’s health.

Sleep, stress, exercise, nutrition, metabolic health, emotional well-being, medications, physical comfort, and relationships can all influence sexual function.

An integrative approach does not mean assuming every symptom requires a supplement or alternative therapy.

It means looking at the whole physiologic and personal environment in which the symptom developed.

Sleep

Poor sleep affects mood, energy, stress regulation, and relationship functioning, all of which can influence sexual interest.

Menopause can make this particularly relevant because night sweats, insomnia, sleep apnea, restless legs, caregiving responsibilities, and stress may all disrupt restorative sleep.

A woman who is chronically exhausted may describe herself as having “no hormones” when sleep deprivation is an important part of the problem.

Addressing sleep does not replace appropriate testosterone therapy for HSDD.

It makes the overall evaluation more complete.

Exercise and Physical Activity

Regular physical activity supports cardiovascular health, metabolic health, mood, physical function, and healthy aging.

Resistance exercise is particularly valuable during midlife because muscle mass and strength become increasingly important for long-term function.

Exercise may also improve body confidence and psychological well-being for some women, which can indirectly support sexual health.

But exercise should not be presented as a simplistic cure for HSDD, just as testosterone should not be marketed as a shortcut to building muscle.

Both interventions should be used for what evidence actually supports.

Nutrition and Metabolic Health

No specific “testosterone diet” has been proven to treat HSDD.

A balanced dietary pattern emphasizing adequate protein, vegetables, fruits, whole grains or other minimally processed carbohydrate sources as appropriate, healthy fats, and overall nutritional adequacy supports general metabolic and cardiovascular health.

Extreme diets or supplements marketed specifically to “boost testosterone” should be approached skeptically.

A woman does not need to maximize testosterone production to be healthy.

The objective is appropriate endocrine function within the context of overall health.

Stress

Sexual desire requires mental space.

Chronic stress can keep the nervous system focused on deadlines, caregiving, financial concerns, health worries, and other demands rather than sexual cues.

Stress reduction is therefore not a dismissal of hormonal symptoms.

It is recognition that the brain is one of the most important sexual organs.

Mindfulness, psychotherapy, couples therapy, relaxation practices, exercise, time away from work, and other strategies may be useful depending on the circumstances.

For women with HSDD, these approaches may complement rather than replace medical therapy.

Relationship and Sexual Context

Desire does not always appear spontaneously.

For many women, particularly in long-term relationships, desire can be responsive. Interest may develop after affectionate or erotic interaction begins rather than appearing beforehand.

Understanding this can be reassuring.

A woman may believe she has lost her sexuality because she no longer experiences spontaneous desire the way she did at age 25, while still being capable of meaningful arousal and enjoyment in the right context.

That does not mean distressing loss of desire should be ignored.

It means sexual health should be evaluated in context rather than reduced to a hormone concentration.

Supplements Marketed for Female Testosterone

Many supplements are marketed as natural testosterone boosters, libido enhancers, adrenal support products, or hormone-balancing formulas.

Evidence for these products varies widely, and many have not been adequately studied for efficacy, purity, drug interactions, or long-term safety.

“Natural” does not automatically mean harmless.

Supplements may also interact with prescription medications or complicate interpretation of symptoms and laboratory testing.

Patients considering supplements for libido or hormone symptoms should discuss them with a pharmacist or healthcare provider, particularly if they take prescription medications or have hormone-sensitive medical conditions.

The Goal Is Physiologic Treatment, Not Hormone Maximization

One of the most useful principles in testosterone therapy is also one of the simplest:

The goal is not to create the highest testosterone level a woman can tolerate.

The goal is to determine whether carefully dosed therapy improves a specific, clinically meaningful problem while keeping testosterone exposure within normal female physiology.

That philosophy protects against two extremes.

The first is dismissing testosterone entirely because it is traditionally thought of as a male hormone.

The second is treating testosterone as an anti-aging drug that every woman should optimize.

Neither reflects the evidence well.

Testosterone is a legitimate female hormone and, for appropriately selected women, a legitimate therapy.

It is also a medication with specific indications, dose considerations, monitoring requirements, and unanswered long-term safety questions.

Both statements can be true at the same time.

Questions to Ask Before Starting Testosterone

Before beginning treatment, consider discussing the following with your healthcare provider:

• What condition are we treating?
• Do my symptoms meet the criteria for HSDD?
• Have other causes of low sexual desire been considered?
• Could any of my medications be contributing?
• Do I have vaginal dryness or pain that needs separate treatment?
• What testosterone formulation are you recommending?
• Why is this route appropriate for me?
• Is the medication FDA approved for this use?
• If it is compounded, why is compounding appropriate in my situation?
• What dose am I actually receiving?
• Where and how should I apply it?
• How do I prevent transfer to another person?
• What baseline laboratory testing do I need?
• When should testosterone be rechecked?
• What side effects should I report?
• How long should we try treatment before deciding whether it works?
• What is the plan if my testosterone concentration becomes too high?

A clinician should be able to answer these questions clearly.

Frequently Asked Questions

Is testosterone normal in women?

Yes. Women naturally produce testosterone and other androgens. Testosterone participates in sexual physiology and has biological effects in multiple tissues. Women normally have much lower circulating testosterone concentrations than men.

Does testosterone drop suddenly at menopause?

Not necessarily. Testosterone generally declines across adulthood, and natural menopause does not produce the same abrupt change in testosterone that occurs with ovarian estrogen production. Removal of both ovaries can produce a more substantial reduction in testosterone.

What is the main evidence-based reason women take testosterone?

The strongest evidence supports systemic testosterone therapy for appropriately evaluated postmenopausal women with hypoactive sexual desire disorder, or HSDD.

Can testosterone help low libido?

Yes, in appropriately selected postmenopausal women with HSDD. Randomized clinical trials have demonstrated improvements in sexual desire and several other dimensions of sexual function.

Can a blood test tell me whether I need testosterone?

No. There is no validated serum testosterone cutoff that diagnoses HSDD. Blood testing is useful primarily for establishing baseline concentrations and preventing excessive exposure during treatment.

What testosterone level should a woman aim for?

Treatment should generally keep testosterone within the physiologic range for premenopausal women based on the laboratory being used. Therapy should not be escalated simply to reach a marketed “optimal” number.

Is testosterone FDA approved for women?

There is currently no FDA-approved testosterone formulation in the United States specifically indicated for women with HSDD. Treatment is therefore generally prescribed off-label or, in selected circumstances, through a compounded preparation.

Is off-label testosterone unsafe?

Not inherently. Off-label prescribing is common in medicine. It means the FDA-approved labeling for the commercial product does not specifically include that use. The quality of the evidence, dose, patient selection, counseling, and monitoring determine whether off-label treatment is clinically appropriate.

Is compounded testosterone FDA approved?

No. Compounded medications are not FDA-approved products and do not undergo the same FDA premarket review for safety, efficacy, and manufacturing consistency. Compounding may nevertheless have a clinical role when an appropriate commercially available product cannot meet a patient’s individual needs.

Is compounded testosterone more natural than commercial testosterone?

Not necessarily. The molecular identity of testosterone does not make a compounded medication inherently safer or more effective. “Bioidentical” describes molecular structure, not regulatory status or clinical superiority.

Is testosterone cream better than testosterone gel?

Both can deliver testosterone through the skin. The appropriate choice depends on the formulation, concentration, vehicle, dispensing system, dosing requirements, tolerability, availability, and clinician’s treatment plan.

How quickly does testosterone work for libido?

Improvement may begin within several weeks, but response should be assessed over a longer therapeutic trial. If meaningful improvement has not occurred after an adequate trial, often by about six months, treatment should be reconsidered rather than continued automatically.

Will testosterone give me facial hair?

Physiologic treatment can increase acne or facial/body hair in some women. These effects become more concerning as testosterone exposure rises above the normal female range.

Can testosterone deepen a woman’s voice?

Voice deepening is a potential virilizing effect of excessive androgen exposure and may not always be fully reversible. New voice changes should be reported promptly.

Does testosterone cause hair loss?

Excessive androgen exposure can contribute to androgenic scalp hair loss in susceptible individuals. Hair changes should be discussed with the prescriber, particularly if testosterone concentrations are elevated.

Will testosterone help me lose weight?

Testosterone is not an established weight-loss treatment for women and should not be prescribed solely for that purpose.

Will testosterone improve my energy?

Some women report changes in energy or well-being, but current evidence does not support testosterone as a general treatment for fatigue or overall well-being in otherwise healthy women. Fatigue has many possible causes and deserves its own evaluation.

Does testosterone build muscle in women?

Testosterone affects muscle physiology, but current evidence does not support prescribing physiologic testosterone therapy to otherwise healthy women solely to increase muscle mass or strength.

Does testosterone improve brain fog?

Testosterone has not been established as a treatment for cognitive symptoms or prevention of cognitive decline in women.

Does testosterone prevent osteoporosis?

Current evidence does not support prescribing testosterone specifically to prevent osteoporosis. Established strategies for bone health should be used when osteoporosis prevention or treatment is the clinical goal.

Can testosterone be used with estrogen and progesterone?

Yes, when clinically appropriate, but testosterone does not automatically need to be included in menopausal hormone therapy. Each hormone should have a specific clinical reason for use.

Should testosterone be used for vaginal dryness?

Systemic testosterone is not the standard first-line treatment for genitourinary syndrome of menopause. Vaginal moisturizers, lubricants, local estrogen, vaginal DHEA, and other treatments may be more appropriate depending on the patient’s circumstances.

Are testosterone pellets recommended?

Major consensus recommendations generally favor approaches that can maintain physiologic female concentrations and be adjusted easily. ACOG recommends considering preparations other than pellets because of limited safety data and the difficulty of removing or rapidly adjusting a pellet after insertion.

Are testosterone injections used in women?

They can be prescribed in some settings, but injections can make it more difficult to avoid peaks and supraphysiologic concentrations. Transdermal therapy has the strongest guideline support for HSDD.

Should testosterone be taken orally?

Oral testosterone is generally not recommended for HSDD because of unfavorable effects on lipid profiles and other pharmacologic considerations.

Can I use my partner’s testosterone gel?

No. Testosterone should be prescribed specifically for the individual patient. Products intended for men may deliver doses far above physiologic female requirements.

Can testosterone rub off on another person?

Topical testosterone can potentially transfer through skin contact. Patients should follow application instructions carefully, wash their hands after application, and take precautions to prevent contact with the treated area.

Can I use testosterone during pregnancy?

No. Testosterone should not be used during pregnancy. Women with pregnancy potential should discuss contraception and reproductive plans with their healthcare provider.

How often should testosterone levels be checked?

Clinical guidance recommends baseline measurement followed by reassessment after treatment begins, commonly within approximately 3 to 6 weeks. After a stable regimen is established, periodic monitoring, often every 4 to 6 months, may be used to ensure testosterone does not become excessive. The exact schedule should be individualized.

If testosterone helps, do I have to take it forever?

Not necessarily. Continued therapy should depend on ongoing benefit, tolerability, safety, and patient preference. Some clinical guidance suggests periodically reassessing whether therapy remains necessary.

A More Thoughtful Way to Think About Testosterone

The conversation around testosterone for women has often swung between two extremes.

For years, testosterone was barely discussed in women’s health.

Now, in some settings, it is marketed as an answer to nearly every symptom of midlife.

The evidence supports a more thoughtful middle ground.

Testosterone is a genuine female hormone. Sexual function is one of its clinically important roles. Carefully dosed testosterone therapy can improve hypoactive sexual desire disorder in appropriately selected postmenopausal women.

But testosterone is not a universal treatment for menopause, fatigue, aging, weight gain, brain fog, or every low laboratory value.

The best care begins by identifying the problem before choosing the hormone.

For a woman experiencing distressing loss of sexual desire, that means asking why desire changed, considering physical and psychological contributors, treating pain or vaginal symptoms when present, reviewing medications and medical conditions, and determining whether the clinical picture is consistent with HSDD.

When testosterone is appropriate, the objective is straightforward:

Use enough to provide meaningful benefit without exceeding normal female physiology.

That requires careful prescribing, appropriate monitoring, realistic expectations, and communication among the patient, prescriber, and pharmacist.

Personalized Testosterone Therapy and the Role of the Compounding Pharmacist

Because there is currently no FDA-approved testosterone formulation specifically designed for women with HSDD in the United States, testosterone treatment can present practical dosing challenges.

Commercial testosterone products intended for men may contain substantially larger doses than women typically require.

When a prescriber determines that a compounded preparation is clinically appropriate for an individual patient, a compounding pharmacist can prepare the prescribed concentration and dosage form and help the patient understand how to measure and use the medication consistently.

At Ion Integrative Pharmacy, our role is not to decide whether every woman needs testosterone.

Our role is to help patients and prescribers use individualized medications carefully when a compounded preparation is appropriate.

That includes helping patients understand:

• Their prescribed concentration and dose
• How to measure the medication accurately
• Proper application technique
• Storage instructions
• Precautions to reduce accidental transfer
• Potential androgenic adverse effects
• The importance of laboratory and clinical follow-up

Hormone therapy works best when the prescriber, pharmacist, and patient understand the same treatment goal.

For testosterone, that goal should never be simply to increase a laboratory number.

It should be to address a well-defined clinical concern with the lowest appropriate exposure, monitor the response, and continually ask the most important question:

Is this treatment meaningfully helping this patient?

When to Speak With Your Healthcare Provider

Consider discussing sexual health with your healthcare provider if you have experienced a persistent change in sexual desire that bothers you, particularly during perimenopause, after menopause, or following ovarian surgery.

You do not need to know whether the problem is “hormonal” before asking for help.

A good evaluation is designed to figure that out.

Sexual health is part of health, and concerns about desire, arousal, orgasm, vaginal dryness, or painful intercourse deserve the same thoughtful medical attention as other symptoms.

If testosterone therapy is being considered, ask why it is being recommended, how it will be dosed, how treatment will be monitored, and what outcome you should expect.

If a compounded testosterone preparation has been prescribed for you, the pharmacist can also help explain the formulation, dosing device, application technique, storage, and medication-specific precautions.

Ion Integrative Pharmacy works with patients and healthcare providers to support individualized compounded hormone therapy when clinically appropriate.

Speak with your healthcare provider about whether testosterone therapy is appropriate for your situation, or contact Ion Integrative Pharmacy if you have questions about a compounded prescription.

We’re here for you.

Important Medical Disclaimer

This article is intended for educational purposes and does not replace individualized medical advice, diagnosis, or treatment.

Testosterone therapy is not appropriate for every patient. Indications, contraindications, dosing, laboratory monitoring, drug interactions, pregnancy considerations, cancer history, cardiovascular risk, and other factors should be evaluated by a qualified healthcare professional.

Compounded medications are prepared for individual patients pursuant to a prescription when clinically appropriate. Compounded medications are not FDA approved, and the FDA does not evaluate compounded preparations for safety, effectiveness, or manufacturing quality before they are dispensed in the same manner as FDA-approved drug products.

Never start, stop, change, or share testosterone or another hormone medication without discussing it with your healthcare provider.

References & Further Reading

1. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. doi:10.1210/jc.2019-01603.
2. Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women’s Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021;18(5):849-867. doi:10.1016/j.jsxm.2020.10.009.
3. American College of Obstetricians and Gynecologists. Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6. Obstet Gynecol. 2023;142:1266-1273. Reaffirmed 2026.
4. American College of Obstetricians and Gynecologists. Female Sexual Dysfunction. ACOG Practice Bulletin No. 213. Obstet Gynecol. 2019;134:e1-e18. Reaffirmed 2025.
5. Wierman ME, Arlt W, Basson R, et al. Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99(10):3489-3510. doi:10.1210/jc.2014-2260.
6. Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. doi:10.1016/S2213-8587(19)30189-5.
7. Jayasena CN, Alkaabi FM, Liebers CS, Handley T, Franks S, Dhillo WS. A systematic review of randomized controlled trials investigating the efficacy and safety of testosterone therapy for female sexual dysfunction in postmenopausal women. Clin Endocrinol (Oxf). 2019;90(3):391-414. doi:10.1111/cen.13906.
8. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab. 2005;90(7):3847-3853. doi:10.1210/jc.2005-0212.
9. Elraiyah T, Sonbol MB, Wang Z, et al. The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99(10):3543-3550. doi:10.1210/jc.2014-2262.
10. U.S. Food and Drug Administration. Testosterone Information. FDA. Updated 2026.
11. The Menopause Society. Sexual Health. Patient Education: Menopause Topics.
12. The Menopause Society. Testosterone Use for Hypoactive Sexual Desire Disorder in Postmenopausal Women. Menopause Practice Pearls.
13. The Menopause Society. Hormone Therapy Misinformation. Position statement regarding evidence-based indications for menopausal hormone therapy and testosterone therapy. 2024.